TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00008411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Every 3 weeks at a starting dose of 75 mg/m2 IV over 1 hour on day 1, repeated every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 35 mg/m2 IV over 30 minutes on days 1, 8, and 15, for 3 weeks followed by one week of rest repeated every 28 days.
Study: NCT04202068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone sodium and Sulbactam Sodium for injection
Description: Ceftriaxone sodium and Sulbactam Sodium for injection is available as sterile powder for reconstitution.It will be administered as one 3g IV dose for adult or one 75mg/kg IV dose for children under 12.
Study: NCT00428935

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV2.5-CMV-minidystrophin (d3990)
Description: Recombinant adeno-associated virus (AAV) carrying a truncated human dystrophin gene (mini-dystrophin) expressed from a cytomegalovirus (CMV) promoter.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV2.5-CMV-minidystrophin (d3990)
Description: Recombinant adeno-associated virus (AAV) carrying a truncated human dystrophin gene (mini-dystrophin) expressed from a cytomegalovirus (CMV) promoter.
Study: NCT01013324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL147 (SAR245408)
Description: dosed as capsules taken orally daily
Study: NCT01453972

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Long distanse moderate training
Description: Moderate exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Long interval training
Description: High-intensity exercise, long duration

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short interval training
Description: High intensity exercise, short duration
Study: NCT00187538

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary
Description: dietary

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary
Description: dietary

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary
Description: dietary
Study: NCT03715881

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Erythropoietin injection
Description: 1000 units of erythropoietin every 12 hours for three days
Study: NCT00187538

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary
Description: dietary
Study: NCT01480726

Intervention type: PROCEDURE
Intervention: Surgery
Study: NCT00868543

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic gastric Roux-en-Y gastric bypass
Description: The fundus is separated by linear cutter. The intestine is opened approximately 75 cm from the ligament of Treitz and approached to the stomach. The gastrojejunostomy is performed in antecolic position The jejunum has to be in an antimesenteric position. After removing the endocutter, the anastomotic incision is closed with a continuous suture. The distance between the gastrojejunostomy and jejunojejunostomy was measured on the antimesenteric border with the bowel on a stretch. The jejunojejunostomy is performed in 150cm distance from gastrojejunostomy. The anastomosis is made by a posterior staple line and an anterior suture line. Preparation of a small window for the endocutter branches into the jejunal mesenterium 2-3 cm proximal to the gastrojejunostomy and above the entero-intestinal anastomosis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic gastric Roux-en-Y gastric bypass
Description: The fundus is separated by linear cutter. The intestine is opened approximately 75 cm from the ligament of Treitz and approached to the stomach. The gastrojejunostomy is performed in antecolic position The jejunum has to be in an antimesenteric position. After removing the endocutter, the anastomotic incision is closed with a continuous suture. The distance between the gastrojejunostomy and jejunojejunostomy was measured on the antimesenteric border with the bowel on a stretch. The jejunojejunostomy is performed in 250cm distance from gastrojejunostomy. The anastomosis is made by a posterior staple line and an anterior suture line. Preparation of a small window for the endocutter branches into the jejunal mesenterium 2-3 cm proximal to the gastrojejunostomy and above the entero-intestinal anastomosis.
Study: NCT00639678

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 40 mg/kg intravenously, double dose (day 0 and 14), Group 3
Study: NCT03767998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training for IMST
Description: 2 sets of 30 breaths or 6 sets of 10 repetitions with one or two minute of rest between sets, once per day, 5 days per week, training with breathing trainer.
Study: NCT01232127

Intervention type: DRUG
Group type: OTHER
Intervention: Atazanavir
Description: Capsule, oral, 300 mg, once daily, 10 days
Study: NCT03767998

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular Rehabilitation
Description: Regular Rehabilitation: 2-3 times a week, 6 weeks.
Study: NCT01232127

Intervention type: DRUG
Group type: OTHER
Intervention: Atazanavir
Description: Capsule, oral, 400 mg, once daily, 7 days

Intervention type: DRUG
Group type: OTHER
Intervention: Atazanavir
Description: Capsule, oral, 400 mg, once daily, 7 days

Intervention type: DRUG
Group type: OTHER
Intervention: Ritonavir
Description: Capsule, oral, 100 mg, once daily, 10 days
Study: NCT03767998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular Rehabilitation
Description: Regular Rehabilitation: 2-3 times a week, 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular Rehabilitation
Description: Regular Rehabilitation: 2-3 times a week, 6 weeks.
Study: NCT00639678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raxibacumab
Description: 40 mg/kg intravenously, double dose (day 0 and 14), Group 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 40 mg/kg placebo, single dose (day 0), Group 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raxibacumab
Description: 40 mg/kg intravenously, single dose, day 0, Group 2
Study: NCT00936559

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMP-655/ACS or Standard of Care
Description: Decision was made by Legal to withhold this information

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMP-655/ACS or Standard of Care
Description: Decision was made by Legal to withhold this information.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMP-655/ACS or Standard of Care
Description: Decision was made by Legal to withhold this information,
Study: NCT01524471

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Per Oral Endoscopic Myotomy
Study: NCT00681083

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heated breathing tube (CPAP with ThermoSmart)
Description: CPAP with ThermoSmart - heated passover humidifier, with heated breathing tube

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non heated breathing tube (CPAP with conventional humidification)
Description: CPAP with conventional humidification - heated passover humidifier, no heated breathing tube
Study: NCT01178957

Intervention type: OTHER
Intervention: Hyperglycemia
Description: Hyperglycemia with a blood glucose of 15 mmol/L
Study: NCT02356575

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavior Therapy
Study: NCT03414060

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Menstrual Cup
Study: NCT02160535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: 155 units of OnabotulinumtoxinA administered intramuscularly. Injections are divided across seven injection specific head/neck muscle areas every 12 weeks to prevent chronic migraine post traumatic headache
Study: NCT02530060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine FDC
Description: Fixed dose combination tablet contains 25 milligram (mg) of Rilpivirine, 300 mg of Tenofovir Disoproxil Fumarate (TDF) and 200 mg of Emtricitabine (FTC).
Study: NCT01501175

Intervention type: OTHER
Intervention: consultation with a vascular physician
Description: As in usual practice, patient with suspected SVT will consult a vascular physician to diagnose SVT and eventually DVP/PE associated. Vascular physician will collect risk factors of SVT.
Study: NCT02370134

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parkinson's glove
Description: Parkinson's glove had module for detection tremor by gyroscope/acceleroscope and suppression rest hand tremor with electrical muscle stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham glove
Study: NCT01227434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332991 (pre-surgery)
Description: PD 0332991 for 7 days prior to an indicated, intended surgical resection for progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332991
Description: PD 0332991 daily for 21 consecutive days followed by a 7 day break off therapy, repeating cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332991
Description: PD 0332991 daily for 21 consecutive days followed by a 7 day break off therapy, repeating cycles

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection as clinical care
Description: Indicated, intended, surgical resection as clinical care
Study: NCT04455113

Intervention type: DIAGNOSTIC_TEST
Intervention: Phosphorus level
Description: infusion

Intervention type: DIAGNOSTIC_TEST
Intervention: Phosphorus level
Description: infusion
Study: NCT04002713

Intervention type: OTHER
Intervention: ALT flap reconstruction
Description: Patients who underwent ALT free flap reconstruction after head and neck cancer surgery.

Intervention type: OTHER
Intervention: AMT flap reconstruction
Description: Patients who underwent AMT free flap reconstruction after head and neck cancer surgery.
Study: NCT02792881

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic completion total gastrectomy with D2 lymphadenectomy
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic completion total gastrectomy with D2 lymphadenectomy will be performed with curative treated intent. For carcinomas arising in the remnant stomach with a gastrojejunostomy, jejunal lymph nodes adjacent to the anastomosis are included as regional lymph nodes. The type of reconstruction will be selected according to the surgeon's experience and the anastomotic procedure will be performed extracorporeally through an auxiliary incision.
Study: NCT02126020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical infliximab
Description: topical infliximab administered QID for 3 months followed by BID for 9 months
Study: NCT03486223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2256294
Description: Drug will be taken daily by mouth for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2256294
Description: Drug will be taken daily by mouth for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Placebo will be taken daily by mouth for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Placebo will be taken daily by mouth for 7 days.
Study: NCT04365296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The purpose of the study is to evaluate which is more effective aerobic or resistance exercises in reducing plasma liver enzymes level (AST and ALT) post burn. Subjects and Methods: Sixty burned patients with burned body surface area about 30% to 50% will participate in this study. Their ages will be ranged from 20-45 years. They will be selected from Orabi Hospital and will be divided randomly into two equal groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The purpose of the study is to evaluate which is more effective aerobic or resistance exercises in reducing plasma liver enzymes level (AST and ALT) post burn. Subjects and Methods: Sixty burned patients with burned body surface area about 30% to 50% will participate in this study. Their ages will be ranged from 20-45 years. They will be selected from Orabi Hospital and will be divided randomly into two equal groups.
Study: NCT01996852

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral Meetings
Description: The cognitive-behavioral intervention will consist of six monthly in-person meetings and five telephone follow-ups. In-person meetings include a 90-minute educational group session and five 60-minute therapeutic couple-based meetings which partners are asked to attend. The telephone follow-ups last 15-30 minutes and take place two weeks after each in-person meeting. They will review progress and provide support.~Each monthly meeting has a focused topic: Introduction, Guided imagery, Sensate focus, Communication and relationship issues, and Review.~Homework will be assigned at the end of each meeting. Generally, participants are instructed (a) practice guided imagery daily, (b) engage in sexual activity 1-2 times/ week after sildenafil intake and (c) use the pump every day for 10min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil citrate
Description: 100mg of sildenafil citrate will be given twice a week to interested patients. Participants may start Sildenafil at a lower dose when needed.~To increase external validity, participants will be given the choice of using Sildenafil in the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate
Description: 100mg of sildenafil citrate will be given twice a week to interested patients. Participants may start Sildenafil at a lower dose when needed.~To increase external validity, participants will be given the choice of using Sildenafil in the study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vacuum Constriction Device
Description: The medical treatment entails a 10-minute daily use of VCD (pump).~The VCD (pump) is a FDA approved marketing product and has a brochure and DVD that explain its usage. The clinical trials unit (CTU) nurse will dispense the VCD at the drug pick-up time and document it on a Device Accountability Form. The study coordinator has received manufacturer's training and can address questions that a subject may have about VCD on site or through a phone call.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vacuum Constriction Device
Description: The medical treatment entails a 10-minute daily use of VCD (pump).~The VCD (pump) is a FDA approved marketing product and has a brochure and DVD that explain its usage. The clinical trials unit (CTU) nurse will dispense the VCD at the drug pick-up time and document it on a Device Accountability Form. The study coordinator has received manufacturer's training and can address questions that a subject may have about VCD on site or through a phone call.
Study: NCT02349321

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skhokho Supporting Success for Schools
Description: All information describing each facet of the intervention are included in the arm/group descriptions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skhokho Supporting Success for Schools
Description: All information describing each facet of the intervention are included in the arm/group descriptions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skhokho Supporting Success for Families
Description: All information describing each facet of the intervention are included in the arm/group descriptions.
Study: NCT02034669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laminectomy
Description: surgical laminectomy with glial scar resection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intradural space
Description: ADSCs injection into Intradural space at damage site
Study: NCT01232127

Intervention type: DRUG
Group type: OTHER
Intervention: Ritonavir
Description: Capsule, oral, 100 mg, once daily, 10 days

Intervention type: DRUG
Group type: OTHER
Intervention: Ritonavir
Description: Capsule, oral, 100 mg, once daily, 7 days
Study: NCT02034669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrathecal
Description: ADSCs Intrathecal into lumbar puncture

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravenous
Description: ADSCs intravenous
Study: NCT01232127

Intervention type: DRUG
Group type: OTHER
Intervention: Tenofovir (TDF)
Description: Capsule, oral, 300 mg, once daily, 10 days

Intervention type: DRUG
Group type: OTHER
Intervention: Tenofovir (TDF)
Description: Capsule, oral, 300 mg, once daily, 7 days

Intervention type: DRUG
Group type: OTHER
Intervention: Tenofovir (TDF)
Description: Capsule, oral, 300 mg, once daily, 7 days

Intervention type: DRUG
Group type: OTHER
Intervention: Nucleoside Reverse Transcriptase Inhibitor (NRTI)
Description: Oral, 10 days

Intervention type: DRUG
Group type: OTHER
Intervention: Nucleoside Reverse Transcriptase Inhibitor (NRTI)
Description: Oral, 7 days

Intervention type: DRUG
Group type: OTHER
Intervention: Nucleoside Reverse Transcriptase Inhibitor (NRTI)
Description: Oral, 7 days
Study: NCT03567304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine 25 mg
Description: Rilpivirine 25 mg PO OD with meal (and continue 2 back bone of NRTIs)
Study: NCT03767998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training for EMST
Description: 5 sets, 5 repetition with one or two minute of rest between sets, twice per day, 5 days per week, training with breathing trainer.
Study: NCT03489850

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibudilast
Description: Ibudilast (IBUD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inhibitory factor.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is matched to ibudilast active medication.
Study: NCT02055170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: finasteride 5mg oral daily
Study: NCT01232127

Intervention type: DRUG
Group type: OTHER
Intervention: Famotidine (FAM)
Description: Tablet, oral, 20 mg, twice daily, 7 days
Study: NCT03320889

Intervention type: OTHER
Group type: OTHER
Intervention: Educational Intervention
Description: Patients will be randomized to a group that receives the pamphlets only and a group that receives the pamphlets and has an expert educator review that pamphlets with them and answer questions.

Intervention type: OTHER
Group type: OTHER
Intervention: Educational Intervention
Description: Patients will be randomized to a group that receives the pamphlets only and a group that receives the pamphlets and has an expert educator review that pamphlets with them and answer questions.
Study: NCT03627143

Intervention type: OTHER
Group type: OTHER
Intervention: KTI activities
Description: The Investigators also plan the following activities to encourage adherence to the guidelines, with an ultimate goal of rhythm or rate control and discharge home for most patients.~1. Selection of one or more local physician champions from both the ED as well as the cardiology group;~2. Review and discussion of the goals of the study, as well as perceived barriers and enablers, by the ED and cardiology physician groups;~3. Formal introduction of the CAEP AAFF Guidelines to the ED physicians and residents by means of presentations at rounds and staff meetings, emails, online video, and web-based resources;~4. Development of local action plan addressing local barriers to implementation;~5. Provision of the free Smartphone App to be developed for the guidelines;~6. Regular reminders provided by the local research staff;~7. Audit and feedback charts of site compliance
Study: NCT02671175

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dihydroartemisinin-piperaquine
Description: Children in both arms will receive standard in-hospital care for severe anaemia (blood transfusion, often combined with quinine or artesunate IV/IM). All children will then receive a 3-day course of AL (whether they initially had malaria or not), which will be started in-hospital as soon as they are able to take oral medication, and will be completed at home after discharge. At 2 weeks after enrolment surviving children will be randomized to receive either a standard 3-day courses of dihydroartemisinin-piperaquine (Eurartesim®, Sigma Tau, Italy) or an identical placebo regimen at 2, 6 and 10 weeks after enrolment.
Study: NCT01232127

Intervention type: DRUG
Group type: OTHER
Intervention: Famotidine (FAM)
Description: Tablet, oral, 40 mg, twice daily, 7 days
Study: NCT03122236

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neurorehabilitation of Standard Walking
Description: Neurorehabilitation is a behavioral therapeutic approach for enhancing the neural control of task performance by: Restoration of function, specificity of training, Sensory input to the nervous system, Intensity, Repetition and Progression of training. Neurorehabilitation of standard walking will focus on the use of typical steady state walking.
Study: NCT00501462

Intervention type: DRUG
Group type: OTHER
Intervention: GSK189075
Description: single 250 mg dose of drug

Intervention type: DRUG
Group type: OTHER
Intervention: GSK189075
Description: single 250 mg dose of drug
Study: NCT02354261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUBA-Itraconazole
Description: Subjects will receive an oral dose of 300 mg SUBA-Itraconazole daily.
Study: NCT00375505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02053922

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntocinon
Description: Syntocinon ampoules (10 IU Oxytocin). (Novartis Pharma, Egypt) One ampoule 10 IU diluted in 10 ml normal saline and administered slowly (over 30- 60 seconds) intravenously just after delivery of the neonate during CS, followed by an intravenous drip of 20 IU oxytocin in 500 ml saline over 4 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Carbetocin (Ampoule 100 μg/ml) . \[Pabal, Marketing Authorization Holder: Ferring GmbH (Gesellschaft mit beschränkter Haftung), Kiel ,Germany. Manufactured by DRAXIS Pharma , a division of specialty Pharmaceuticals Inc. Montreal ,Canada\] ,diluted in 10 ml normal saline and administered slowly (over 30- 60 seconds) intravenously just after delivery of the neonate during CS.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol (200 mcg Tablet) \[Misotac, Sigma Pharmaceutical Industries, SAE, Egypt\] Two tablets (400 mcg) in the buccal space just after delivery of the neonate during CS.